Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On Thursday 19 April, Oxford University will play host to an AIMday focused on Biomedical Imaging, which is at the heart of much of the clinical and biomedical research conducted at the University.

Following successful AIMdays focusing on Microscopy and Ageing, in April the Divisional Business Development Team will be running an AIMday in Biomedical Imaging, a broad topic which offers the opportunity to discuss the analysis, enhancement and display of images captured via x-ray, ultrasound, MRI, nuclear medicine and optical imaging technologies. A range of companies including GSK, GE Healthcare, Siemens, and Blue Earth Diagnostics are registered to attend, and it is a fantastic chance for researchers looking to network with industry and discuss relevant questions.

AIMdays are a concept which offer a unique way to facilitate interaction between industry and academia. Born at the University of Uppsala in 2008, they have increasingly gathered attention and use at universities across the globe looking to match researchers with industrial partners.

Interested industry partners are invited to submit questions around a certain topic. At the Microscopy AIMday run in Oxford last year, companies including Zeiss, Olympus, and Andor Technology submitted questions around imaging technologies to aid medical diagnostics, use of virtual reality to understand biological processes, and novel techniques for the future of microscopy research.

Academics then choose which of these questions they would like to answer, depending on their particular area of expertise. The AIMday algorithm designs a programme of one-hour sessions that matches industry partners and academics by their shared interests so that sessions can run in parallel, and interaction between industry and academics is maximised. 

Martin Kerr, Business Development Manager and organiser of the AIMday commented: 'AIMdays are a fantastic opportunity for researchers to spark new collaborations, build their networks, and get a fresh perspective on how their work could be translatable. It also offers early stage researchers exposure to the career paths offered by industry.' 

AIMday Biomedical Imaging takes place on Thu 19 April.  Academic registration opens on Mon 26 Feb – find out more and register.

If you would like to find out more about running an AIMday, please contact Martin Kerr

Similar stories

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.

Oxford overseas research facility expands to include diagnostics and genetics testing centre

The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).